Cost-Effectiveness Analysis of 12-Versus 4-Weekly Administration of Bone-Targeted Agents in Patients with Bone Metastases from Breast and Castration-Resistant Prostate Cancer
A cost–utility analysis was performed based on the Rethinking Clinical Trials (REaCT) bone-targeted agents (BTA) clinical trial that compared 12-weekly (once every 12 weeks) (<i>n</i> = 130) versus 4-weekly (once every 4 weeks) (<i>n</i> = 133) BTA dosing for metastatic breas...
Main Authors: | Megan M. Tu, Mark Clemons, Carol Stober, Ahwon Jeong, Lisa Vandermeer, Mihaela Mates, Phillip Blanchette, Anil Abraham Joy, Olexiy Aseyev, Gregory Pond, Dean Fergusson, Terry L. Ng, Kednapa Thavorn |
---|---|
Format: | Article |
Language: | English |
Published: |
MDPI AG
2021-05-01
|
Series: | Current Oncology |
Subjects: | |
Online Access: | https://www.mdpi.com/1718-7729/28/3/171 |
Similar Items
-
Real-world practice patterns and attitudes towards de-escalation of bone-modifying agents in patients with bone metastases from breast and prostate cancer: A physician survey
by: Mashari AlZahrani, et al.
Published: (2021-02-01) -
Two-year results of a randomised trial comparing 4- versus 12-weekly bone-targeted agent use in patients with bone metastases from breast or castration-resistant prostate cancer
by: Mark Clemons, et al.
Published: (2021-10-01) -
Effects on bone resorption markers of continuing pamidronate or switching to zoledronic acid in patients with high risk bone metastases from breast cancer
by: J.F. Hilton, et al.
Published: (2018-03-01) -
Targeted Treatments of Bone Metastases in Patients with Lung Cancer
by: Vera eHirsh
Published: (2014-06-01) -
Advantages and Disadvantages of Bone Protective Agents in Metastatic Prostate Cancer: Lessons Learned
by: Christian Thomas, et al.
Published: (2016-08-01)